The strategy of combining a HER2 blockade with hormonal therapy and/or CDK4 and 6 inhibitors may provide an opportunity to address the need to de-escalate chemotherapy in patients with HR+/HER2+ BC. The gene discussed is ERBB2; the disease is breast cancer.